198 related articles for article (PubMed ID: 36842685)
1. Effectiveness of thromboprophylaxis with low molecular weight heparin in critically ill patients with COVID-19. An observational prospective, multicenter study.
Ferrandis R; Escontrela B; Ferrando C; Hernández M; Herrera J; Hidalgo F; Librero J; Llau JV; Martínez A; Pajares A; Tapia B; Arruti E; Bassas E; Blasi A; Calvo A;
Rev Esp Anestesiol Reanim (Engl Ed); 2023 Mar; 70(3):129-139. PubMed ID: 36842685
[TBL] [Abstract][Full Text] [Related]
2. [Effectiveness of thromboprophylaxis with low molecular weight heparin in critically ill patients with COVID-19. An observational prospective, multicenter study].
Ferrandis R; Escontrela B; Ferrando C; Hernández M; Herrera J; Hidalgo F; Librero J; Llau JV; Martínez A; Pajares A; Tapia B; Arruti E; Bassas E; Blasi A; Calvo A;
Rev Esp Anestesiol Reanim; 2023 Mar; 70(3):129-139. PubMed ID: 35340761
[TBL] [Abstract][Full Text] [Related]
3. The effect of low-dose and high-dose low-molecular-weight-heparin and aspirin thromboprophylaxis on clinical outcome and mortality in critical ill patients with COVID-19: A retrospective cohort study.
Eman A; Balaban O; Süner KÖ; Cırdı Y; Şahin F; Demir G; Pekşen Ö; Musmul A; Erdem AF
Saudi Med J; 2022 Jul; 43(7):715-722. PubMed ID: 35830988
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 thromboprophylaxis. New evidence.
Ferrandis R; Sierra P; Gomez-Luque A
Rev Esp Anestesiol Reanim (Engl Ed); 2024 Jan; 71(1):34-47. PubMed ID: 37678450
[TBL] [Abstract][Full Text] [Related]
5. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
[TBL] [Abstract][Full Text] [Related]
6. Anti-Xa Directed Thromboprophylaxis in Critically Ill Patients with Coronavirus Disease 2019.
Mohamed A; Shemanski SM; Saad MO; Ploetz J; Haines MM; Schlachter AB; Hamarshi MS
Clin Appl Thromb Hemost; 2022; 28():10760296221116350. PubMed ID: 35924413
[No Abstract] [Full Text] [Related]
7. Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients.
Volteas P; Drakos P; Alkadaa LN; Cleri NA; Asencio AA; Oganov A; Giannopoulos S; Saadon JR; Mikell CB; Rubano JA; Labropoulos N; Tassiopoulos AK; Mofakham S; Bannazadeh M
J Vasc Surg Venous Lymphat Disord; 2022 Sep; 10(5):1128-1136. PubMed ID: 35716998
[TBL] [Abstract][Full Text] [Related]
8. Low molecular weight heparin for prevention of central venous catheter-related thrombosis in children.
Pelland-Marcotte MC; Amiri N; Avila ML; Brandão LR
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD005982. PubMed ID: 32557627
[TBL] [Abstract][Full Text] [Related]
9. Thromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations-State-of-the-Art.
Dimakakos E; Gomatou G; Catalano M; Olinic DM; Spyropoulos AC; Falanga A; Maraveyas A; Liew A; Schulman S; Belch J; Gerotziafas G; Marschang P; Cosmi B; Spaak J; Syrigos K;
Anticancer Res; 2022 Jul; 42(7):3261-3274. PubMed ID: 35790272
[TBL] [Abstract][Full Text] [Related]
10. What is the effect of low-molecular weight heparin for venous thromboembolism prophylaxis compared with mechanical methods, on the occurrence of hemorrhagic and venous thromboembolic complications in patients with intracerebral hemorrhage? A critically appraised topic.
O'Carroll CB; Capampangan DJ; Aguilar MI; Bravo TP; Hoffman-Snyder CR; Wingerchuk DM; Wellik KE; Demaerschalk BM
Neurologist; 2011 Jul; 17(4):232-5. PubMed ID: 21712672
[TBL] [Abstract][Full Text] [Related]
11. The impact of protocol-based high-intensity pharmacological thromboprophylaxis on thrombotic events in critically ill COVID-19 patients.
Atallah B; Sadik ZG; Salem N; El Nekidy WS; Almahmeed W; Park WM; Cherfan A; Hamed F; Mallat J
Anaesthesia; 2021 Mar; 76(3):327-335. PubMed ID: 33047335
[TBL] [Abstract][Full Text] [Related]
12. Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review.
Ribic C; Lim W; Cook D; Crowther M
J Crit Care; 2009 Jun; 24(2):197-205. PubMed ID: 19327323
[TBL] [Abstract][Full Text] [Related]
13. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Candeloro M; De Tursi M; Russi I; Rutjes AW
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008500. PubMed ID: 27906452
[TBL] [Abstract][Full Text] [Related]
14. Thromboembolic events in COVID-19 ambulatory patients: An observational study about incidence, and thromboprophylaxis outcomes.
Hammami R; Jdidi J; Chakroun O; Issaoui F; Ktata N; Maamri H; Baklouti M; Bahloul A; Gargouri R; Nasri A; Msaad S; Kammoun S; Kammoun S; Rejab IB; Charfeddine S; Abid L
PLoS One; 2022; 17(8):e0270195. PubMed ID: 35925930
[TBL] [Abstract][Full Text] [Related]
15. Thromboprophylaxis in Hospitalized Non-Critically Ill Patients With Mild-to-Moderate COVID-19 Infection: A Systematic Review and Meta-Analysis.
Hafiz A; Alkofide H; Al Sulaiman K; Joharji H; Aljohani S; Sarkhi KA; Alharbi R; Korayem GB; AlFaifi M; Alsohimi S; Aljuhani O
Clin Appl Thromb Hemost; 2023; 29():10760296231191123. PubMed ID: 37547931
[TBL] [Abstract][Full Text] [Related]
16. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery.
Felder S; Rasmussen MS; King R; Sklow B; Kwaan M; Madoff R; Jensen C
Cochrane Database Syst Rev; 2019 Aug; 8(8):CD004318. PubMed ID: 31449321
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic-dose anticoagulation or thromboprophylaxis with low-molecular-weight heparin for moderate Covid-19: meta-analysis of randomized controlled trials.
Ena J; Valls V
Clin Exp Med; 2023 Aug; 23(4):1189-1196. PubMed ID: 36048371
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological and Mechanical Thromboprophylaxis in Critically Ill Patients: a Network Meta-Analysis of 12 Trials.
Park J; Lee JM; Lee JS; Cho YJ
J Korean Med Sci; 2016 Nov; 31(11):1828-1837. PubMed ID: 27709864
[TBL] [Abstract][Full Text] [Related]
19. Risk assessment and prophylaxis of venous thromboembolism in acutely and/or critically ill patients.
Davidson BL
Haemostasis; 2000; 30 Suppl 2():77-81; discussion 63. PubMed ID: 11251346
[TBL] [Abstract][Full Text] [Related]
20. Pragmatic Recommendations for the Management of Anticoagulation and Venous Thrombotic Disease for Hospitalized Patients with COVID-19 in Low- and Middle-Income Countries.
Ahmed HY; Papali A; Haile T; Shrestha GS; Schultz MJ; Lundeg G; Akrami KM;
Am J Trop Med Hyg; 2021 Jan; 104(3_Suppl):99-109. PubMed ID: 33432908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
